Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Petros Grivas, ASCO GU22: Current Unmet Needs in the Treatment of Metastatic Urothelial Cancer

3 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 28th 2022

touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Question

  1. What are the current unmet educational needs in the treatment of metastatic urothelial cancer? (00:16-03:00)

Speaker Disclosure: Dr Petros Grivas discloses consultancy/advisory board participation for Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Exelixis, Roche, Genentech, Dyania Health, Mirati Therapeutics, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma and Gilead Sciences. Dr Petros Grivas also disclosed research funding from Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, Kure It Cancer Research, GlaxoSmithKline, Mirati Therapeutics, EMD Serono and G1 Therapeutics.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup